Introduction {#sec1-2055217318787826}
============

Although increasing numbers of treatments are available for multiple sclerosis (MS), the exact mechanism of action of these therapies is often unclear. Patients are frequently required to trial several treatments to identify which is most suitable for their disease activity. Dimethyl fumarate (DMF; Tecfidera, Biogen Idec, Cambridge MA, USA) is approved in Europe and Australia as a first-line oral drug for the treatment of relapsing--remitting multiple sclerosis, and its use is associated with a reduction in disease activity and a variable effect on progression.^1,2^

Although the exact mode of action is not fully elucidated, DMF has been shown to have both anti-inflammatory and anti-oxidative properties. Decreased absolute lymphocyte counts and a shift in T lymphocyte polarisation from T helper (Th)1 and Th17 (pro-inflammatory) to Th2 phenotype (anti-inflammatory) has been reported after DMF treatment in MS patients.^3^ DMF also promotes translocation of nuclear factor erythroid 2-related factor 2 into the nucleus, which upregulates the transcription of anti-oxidative enzymes.^3^

DNA methylation refers to the epigenetic modification whereby the addition/removal of methyl groups to CpG dinucleotides regulates gene transcription. We, and others, have assessed global methylation profiles in CD4^+^ and CD8^+^ T cells from MS patients compared to healthy controls.^4--6^ Our studies have demonstrated altered methylation profiles in the CD4^+^ T cells of treatment-naive patients or in the absence of treatment. However, the effect of disease-modifying therapies (DMTs) on methylation profiles remains unclear. Neither group found significant changes in CD8^+^ T cells.^5,6^

Here we performed a longitudinal study of the genome-wide methylation profiles of CD4^+^ T cells in MS patients before and after DMF treatment.

Methods {#sec2-2055217318787826}
=======

We recruited seven MS patients (three men and four women) who were either treatment naive or had been off DMT for at least 3 months and were planning to start DMF therapy ([Table 1](#table1-2055217318787826){ref-type="table"}). The majority of patients had not had steroid use for at least 2 months prior to entry into this study ([Table 1](#table1-2055217318787826){ref-type="table"}). Samples were collected and processed as previously described.^7^ Blood was collected prior to the first dose of DMF and 6 months following treatment initation. At 6 months, all patients remained on therapy and had no change in Expanded Disability Status Score (EDSS). Two patients had evidence of disease activity as assessed by the appearance of new lesions on magnetic resonance imaging (MRI). However, both of these patients showed no new disease activity at their next MRI and remain on therapy.

###### 

MS cohort demographic/clinical features at baseline (prior to DMF treatment).

![](10.1177_2055217318787826-table1)

  Sex   Age (years)   Prior DMT                                    Prior steroids (days prior to collection)   EDSS at baseline   EDSS at 6 months
  ----- ------------- -------------------------------------------- ------------------------------------------- ------------------ ------------------
  M     23            Naive                                        312                                         1                  1
  M     40            Naive                                        7                                           3                  3
  M     35            Naive                                        54                                          1.5                1.5
  F     32            Naive                                        3400                                        2.5                2.5
  F     42            (Fingolimod)                                 1224                                        3                  3
  F     31            (Glatiramer acetate)                         72                                          1.5                1.5
  F     43            (Peginterferon beta-1a,interferon beta-1a)   95                                          2                  2

MS: multiple sclerosis; DMF: dimethyl fumarate; DMT: disease-modifying therapy; EDSS: Expanded Disability Scale Status.

CD4^+^ T cells were extracted using magnetic isolation kits (Stem Cell Technologies, Canada) and purity (mimimum threshold ≥90%) was assessed using the FACS CantoII (BD Biosciences) system. Purified DNA was bisulphite converted and hybridised to Illumina EPIC arrays. Raw fluorescence data were processed using a combination of R/Bioconductor and custom scripts. Differences in mean methylation before and after the 6-month treatment period were tested using a paired samples *t*-test for each CpG. A CpG was considered a differentially methylated position (DMP) if the *P* value was less than 0.0005 and the absolute difference in mean methylation between groups was greater than 5%. A differentially methylated region (DMR) was defined as two or more contiguous DMPs located within 500 bp of each other, whose methylation changes were in the same direction. If a DMP was located outside of the 500 bp region but was less than 500 bp from the last DMP it was also included in the DMR.

Results and discussion {#sec3-2055217318787826}
======================

In total, 945 DMPs were identified when comparing the 6-month time point to baseline, the majority of which were hypermethylated after treatment (912; 97%) (see Supplementary Table 1). The most altered DMP between baseline and treatment was 17.5% hypermethylated (cg14048158); however, this site maps to an area with no known gene association. To identify sites of potential functional consequence, we filtered DMPs to include only those with a DMR, gene name and position annotation. [Table 2](#table2-2055217318787826){ref-type="table"} shows the DMPs with the largest percentage change for each of the resulting 64 genes.

###### 

DMRs with gene name and annotation.

![](10.1177_2055217318787826-table2)

  Chr.   CpG ID       Position    Gene name        Element   Mean methylation   \% Change   T stat.   *P* value   
  ------ ------------ ----------- ---------------- --------- ------------------ ----------- --------- ----------- ----------------
  1      cg16144718   23115066    *EPHB2*          Body      0.50               0.62        11.47     7.06        4.05 × 10^--4^
  1      cg06808725   32264502    *SPOCD1*         Body      0.44               0.56        11.74     6.64        5.64 × 10^--4^
  1      cg24533227   42145514    *HIVEP3*         5′UTR     0.65               0.76        10.63     6.71        5.32 × 10^--4^
  1      cg02410801   55046065    *ACOT11*         Body      0.56               0.66        9.02      8.87        1.15 × 10^--4^
  1      cg25130912   201982886   *ELF3*           Body      0.66               0.76        9.67      7.11        3.89 × 10^--4^
  2      cg05333614   1168186     *SNTG2*          Body      0.72               0.77        5.36      7.77        2.40 × 10^--4^
  2      cg03771015   15831147    *LOC101926966*   Body      0.62               0.70        7.78      6.35        7.16 × 10^--4^
  2      cg14501323   31279457    *GALNT14*        Body      0.81               0.87        6.37      6.96        4.38 × 10^--4^
  2      cg10796691   65135899    *LOC400958*      Body      0.60               0.69        8.36      9.16        9.53 × 10^--5^
  2      cg16603943   121614683   *GLI2*           Body      0.51               0.63        11.66     6.35        7.13 × 10^--4^
  2      cg20772458   158983130   *UPP2*           Body      0.74               0.80        5.89      7.26        3.46 × 10^--4^
  2      cg18707238   218688237   *TNS1*           Body      0.73               0.78        5.52      6.47        6.49 × 10^--4^
  3      cg15756415   14932169    *FGD5*           Body      0.42               0.54        12.05     6.48        6.40 × 10^--4^
  3      cg02790932   23373256    *UBE2E2*         Body      0.65               0.72        7.55      8.65        1.31 × 10^--4^
  3      cg00049674   123058535   *ADCY5*          Body      0.61               0.68        7.51      7.01        4.20 × 10^--4^
  5      cg27073488   14262157    *TRIO*           Body      0.70               0.75        5.39      8.81        1.19 × 10^--4^
  5      cg16375820   55289001    *IL6ST*          5′UTR     0.31               0.23        --7.30    --9.25      9.03 × 10^--5^
  5      cg27346756   90431802    *ADGRV1*         Body      0.58               0.64        6.52      7.38        3.18 × 10^--4^
  5      cg16558774   132579360   *FSTL4*          Body      0.68               0.75        6.66      9.33        8.58 × 10^--5^
  5      cg11988321   138725622   *MZB1*           TSS200    0.42               0.54        12.21     16.30       3.39 × 10^--6^
  6      cg04095776   31106941    *PSORS1C1*       Body      0.66               0.72        6.25      7.34        3.28 × 10^--4^
  6      cg19978379   31542671    *TNF*            TSS1500   0.54               0.67        13.00     7.09        3.95 × 10^--4^
  6      cg15496866   40491590    *LRFN2*          5′UTR     0.61               0.72        11.04     7.47        2.97 × 10^--4^
  6      cg01473948   148823785   *SASH1*          Body      0.59               0.66        7.47      6.91        4.54 × 10^--4^
  7      cg13800949   47343103    *TNS3*           Body      0.79               0.85        5.90      8.14        1.85 × 10^--4^
  7      cg14797899   69882555    *AUTS2*          Body      0.68               0.78        9.85      7.70        2.51 × 10^--4^
  7      cg02170577   104939331   *SRPK2*          Body      0.72               0.77        5.03      6.94        4.44 × 10^--4^
  7      cg05476934   133859100   *LRGUK*          Body      0.52               0.60        8.64      6.74        5.18 × 10^--4^
  7      cg09891341   138619424   *KIAA1549*       Body      0.78               0.84        6.24      6.81        4.90 × 10^--4^
  7      cg06679384   158049077   *PTPRN2*         Body      0.60               0.66        6.23      7.57        2.76 × 10^--4^
  9      cg08290373   8633541     *PTPRD*          Body      0.68               0.78        10.02     6.66        5.52 × 10^--4^
  9      cg17557530   90193634    *DAPK1*          Body      0.61               0.73        12.22     6.62        5.74 × 10^--4^
  9      cg06749278   97662692    *C9orf3*         Body      0.75               0.83        7.50      6.91        4.55 × 10^--4^
  10     cg16203213   45398814    *TMEM72-AS1*     Body      0.66               0.74        7.24      9.01        1.05 × 10^--4^
  10     cg26754789   49857879    *ARHGAP22*       Body      0.74               0.79        5.36      9.19        9.34 × 10^--5^
  10     cg13312268   50019744    *WDFY4*          ExonBnd   0.72               0.78        6.84      6.68        5.44 × 10^--4^
  10     cg12552633   71573337    *COL13A1*        Body      0.45               0.55        10.40     6.72        5.29 × 10^--4^
  10     cg24587741   79313774    *KCNMA1*         Body      0.68               0.75        7.07      6.89        4.62 × 10^--4^
  10     cg17753789   81026766    *ZMIZ1*          Body      0.69               0.76        7.74      6.52        6.21 × 10^--4^
  10     cg16035098   118886914   *SHTN1*          TSS1500   0.46               0.55        9.16      9.66        7.04 × 10^--5^
  10     cg01613414   126693304   *CTBP2*          Body      0.52               0.62        10.31     7.40        3.13 × 10^--4^
  11     cg09731767   503628      *RNH1*           5′UTR     0.53               0.61        7.79      9.85        6.32 × 10^--5^
  11     cg11922498   4936427     *OR51G2*         1stExon   0.65               0.71        6.09      9.45        7.99 × 10^--5^
  11     cg00842359   10686144    *MRVI1*          5′UTR     0.67               0.77        9.37      9.28        8.85 × 10^--5^
  11     cg14595291   35993855    *LDLRAD3*        5′UTR     0.50               0.65        14.89     6.42        6.76 × 10^--4^
  11     cg00964019   117593395   *DSCAML1*        Body      0.76               0.82        5.81      7.08        3.97 × 10^--4^
  12     cg11439695   2561024     *CACNA1C*        Body      0.46               0.56        9.93      8.25        1.71 × 10^--4^
  12     cg17451712   122293122   *HPD*            Body      0.68               0.75        7.13      6.57        5.95 × 10^--4^
  14     cg03725784   61992305    *PRKCH*          Body      0.41               0.54        12.42     7.14        3.81 × 10^--4^
  14     cg11198334   75040680    *LTBP2*          Body      0.63               0.74        10.81     6.90        4.56 × 10^--4^
  14     cg07399096   91050031    *TTC7B*          Body      0.69               0.75        6.38      6.58        5.91 × 10^--4^
  14     cg15325186   102562217   *HSP90AA1*       Body      0.51               0.60        8.52      7.79        2.36 × 10^--4^
  15     cg25814224   51572976    *CYP19A1*        5′UTR     0.65               0.71        6.39      10.93       3.49 × 10^--5^
  16     cg02260059   78262124    *WWOX*           Body      0.72               0.78        5.78      6.62        5.74 × 10^--4^
  17     cg04456720   54250143    *ANKFN1*         Body      0.67               0.77        10.60     8.93        1.10 × 10^--4^
  17     cg19439071   74557625    *SNORD1A*        TSS200    0.56               0.67        10.87     8.68        1.29 × 10^--4^
  17     cg11476241   78866235    *RPTOR*          Body      0.56               0.66        10.10     6.45        6.58 × 10^--4^
  18     cg13297582   13288627    *LDLRAD4*        5′UTR     0.51               0.62        10.73     7.79        2.36 × 10^--4^
  18     cg03385871   46311648    *CTIF*           Body      0.45               0.56        11.75     6.56        6.00 × 10^--4^
  19     cg07345937   1175444     *SBNO2*          TSS1500   0.53               0.63        9.74      10.58       4.19 × 10^--5^
  20     cg10453816   37499530    *PPP1R16B*       Body      0.51               0.64        13.41     6.85        4.74 × 10^--4^
  20     cg04991444   50057438    *NFATC2*         Body      0.41               0.53        12.25     9.96        5.94 × 10^--5^
  21     cg10919441   44143035    *PDE9A*          5′UTR     0.67               0.73        6.59      7.18        3.68 × 10^--4^

DMT: disease-modifying therapy; Chr.: chromosome.

Four genes had at least two adjacent DMPs located in the transcriptional start site (TSS) ([Table 3](#table3-2055217318787826){ref-type="table"}). *SNORD1A* (small nucleolar RNA, C/D box 1A) encodes for an uncharacterised small nucleolar RNA. *SHTN1* encodes shootin1, a protein involved in neuronal polarisation of axons.^8^ *MZB1* (marginal zone B and B1 cell-specific protein) codes for an endoplasmic reticulum calcium regulator. While it has not previously been linked to MS, a study by Belkaya et al. (2013) found that overexpression of miR-185 resulted in a nearly five-fold decrease of *MZB1* in mice.^9^ This decrease corresponded with lymphopenia and a reduced proliferative response in CD4^+^ T cells.^9^ The observed increase in DNA methylation identified in the *MZB1* TSS in our dataset may result in a similar decrease in *MZB1* transcription. A resulting decrease in CD4^+^ T cells would be consistent with the known anti-inflammatory action of DMF.

###### 

Genes with DMRs in the transcriptional start site.

![](10.1177_2055217318787826-table3)

  Chr.   CpG ID       Position    Gene name   Element   Mean methylation   \% Change   T stat.    *P* value   
  ------ ------------ ----------- ----------- --------- ------------------ ----------- ---------- ----------- ----------------
  5      cg11988321   138725622   *MZB1*      TSS200    0.421426           0.543513    12.20872   16.29927    3.39 × 10^--6^
  5      cg04359635   138725975   *MZB1*      TSS1500   0.513568           0.633291    11.97221   6.619687    5.72 × 10^--4^
  6      cg19978379   31542671    *TNF*       TSS1500   0.537903           0.667883    12.99794   7.088953    3.95 × 10^--4^
  6      cg24452282   31542740    *TNF*       TSS1500   0.470376           0.584539    11.41626   6.396426    6.88 × 10^--4^
  10     cg16035098   118886914   *SHTN1*     TSS1500   0.458233           0.549798    9.156483   9.664102    7.04 × 10^--5^
  10     cg23251794   118886883   *SHTN1*     TSS1500   0.641729           0.707866    6.613676   9.553839    7.51 × 10^--5^
  17     cg19439071   74557625    *SNORD1A*   TSS200    0.562719           0.671405    10.86864   8.67833     1.29 × 10^--4^
  17     cg07180212   74557703    *SNORD1A*   TSS200    0.62678            0.726408    9.962796   6.422776    6.73 × 10^--4^
  17     cg13664588   74557494    *SNORD1A*   TSS1500   0.527718           0.624507    9.678917   6.578915    5.92 × 10^--4^

DMR: differentially methylated region; Chr.: chromosome.

The fourth DMR identified is located at the TSS of tumour necrosis factor (*TNF*)*. TNF* is a pro-inflammatory cytokine that is produced by many cell types, including lymphocytes (reviewed in Wajant *et al*).^10^ TNF binding to its receptor activates the nuclear factor kappa B (NF-κB) pathway, which activates the transcription of genes involved in cell survival and proliferation, inflammatory response and anti-apoptotic factors. Hypermethylation at the *TNF* TSS may result in decreased TNF production, and a decrease in activation of the NF-κB pathway. One known mechanism of action for DMF is preventing translocation of NF-κB to the nucleus, resulting in a decrease of pro-inflammatory cytokines and an increase of anti-inflammatory cytokines (reviewed in Pistono et al.).^3^ It is possible that altered DNA methylation profiles at the *TNF* TSS may contribute to this mechanism.

DMF has previously been linked to other epigenetic mechanisms in a study by Kalinin et al. (2013), in which they reported that DMF increased expression of histone deacetylases in cultured rat astrocytes.^11^ Both DNA methylation and histone deacetylation are associated with gene repression.^12^ Taken together there is now evidence that DMF may act as an epigenetic modifier with the function of shutting down transcription associated with pro-inflammatory activity.

One limitation of this study is that we only assessed patients who started DMF treatment. Also, athough the majority of patients were stable at the time of baseline collection, two patients had recently had a relapse, only one of whom was treated with steroids. We are therefore unable to determine for certain if the changes in methylation profiles are due to treatment effects or stabilisation of disease. Future studies comparing changes following different therapies and different disease severities are required. A further limitation is the small sample size and lack of transcriptional data. Future studies characterising treatment responses in larger populations that also investigate the functional changes at the transcriptional level are warranted.

This is the first longitudinal study to investigate the effect of DMF on the DNA methylation of CD4^+^ T cells of MS patients. Of the most interest, the DMRs identified at *TNF* and *MZB1* provide a potential novel mechanism of action for DMF. Treatment with DMF resulted in overall hypermethylation suggesting that DMF may act to promote DNA methylation. Larger studies are warranted to elucidate further the functional link between DMF and epigenetic mechanisms.
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